06/23/22 7:30 AMNasdaq : CGTX clinical triallow floatCognition Therapeutics Doses First Patient with Dementia with Lewy Bodies in Phase 2 Clinical Study of CT1812Cognition Therapeutics , Inc. (Nasdaq: CGTX) today announced that the first patient hasRHEA-AIpositive
06/08/22 7:30 AMNasdaq : CGTX low floatCognition Therapeutics Announces Presentation at the Upcoming JMP Securities Life Sciences ConferenceCognition Therapeutics, Inc. (Nasdaq: CGTX) announced that the company will participate in the JMP Securities Life Sciences Conference on June 16th. Lisa Ricciardi, Cognition’s president and CEO will be presenting an update on the company'sRHEA-AIneutral
06/02/22 4:01 PMNasdaq : CGTX conferenceslow floatCognition Therapeutics to Host Virtual KOL Symposium on Dry Age-related Macular Degeneration and the Potential for Sigma-2 ModulationCognition Therapeutics, Inc. (Nasdaq: CGTX), announced plans to hold a virtual KOL symposium on June 9, 2022, from 10:00 - 11:30 a.m. ET to discuss dry age-related macular degeneration (dry AMD). CognitionRHEA-AIneutral
05/13/22 7:30 AMNasdaq : CGTX conferenceslow floatCognition Therapeutics to Participate in H.C. Wainwright Global Investment ConferenceCognition Therapeutics, Inc. (Nasdaq: CGTX), a clinical-stage neuroscience company developing therapies that treat age-related degenerative diseases of the central nervous system and retina (the “Company” or “Cognition”), today announced that LisaRHEA-AIneutral
05/11/22 7:00 AMNasdaq : CGTX earningslow floatCognition Therapeutics Reports First Quarter 2022 Financial Results and Provides Business UpdateCognition Therapeutics, Inc. (NASDAQ: CGTX), aRHEA-AIvery positive
05/04/22 5:54 PMNasdaq : CGTX conferencesearningslow floatCORRECTION -- Cognition Therapeutics to Report First Quarter 2022 Financial Results on May 11, 2022In a release issued under the same headline earlier today by Cognition Therapeutics, Inc. (NASDAQ: CGTX), please note that in the first paragraph of the release, the report date should be Wednesday, May 11, 2022, not Tuesday as previously stated.RHEA-AIneutral
05/04/22 4:01 PMNasdaq : CGTX conferencesearningslow floatCognition Therapeutics to Report First Quarter 2022 Financial Results on May 11, 2022Cognition Therapeutics, Inc. (NASDAQ: CGTX), a clinical-stage neuroscience company developing therapies that treat age-related degenerative diseases of the central nervous system and retina (the “Company” or “Cognition”), today announced that itRHEA-AIneutral
05/03/22 8:00 AMNasdaq : CGTX low floatCognition Therapeutics Presented Preclinical Findings Showing that Sigma-2 Receptor Modulators Rescue Trafficking Deficits in Retinal Pigment Epithelial Cells in Model of Dry AMDCognition Therapeutics , Inc. (NASDAQ: CGTX), a clinical stage neuroscience company developing therapies that treat age-related degenerative diseases of the central nervous system and retina, presented a poster today at the annual meeting of TheRHEA-AInegative
04/25/22 4:01 PMNasdaq : CGTX conferencesclinical triallow floatCognition Therapeutics to Present Preclinical Results Demonstrating Therapeutic Potential for Sigma-2 Receptor Modulators in Dry Age-Related Macular DegenerationCognition Therapeutics , Inc. (NASDAQ: CGTX), a clinical stage neuroscience company developing drugs that treat age-related degenerative diseases of the central nervous system and retina, will be presenting a poster at the annual meeting of TheRHEA-AIneutral
04/25/22 8:00 AMNasdaq : CGTX low floatCognition Therapeutics Announces Participation in B. Riley Securities 2022 Virtual Neuro & Ophthalmology ConferenceCognition Therapeutics, Inc. (Nasdaq: CGTX), a clinical stage neuroscience company developing drugs to treat age-related degenerative diseases of the central nervous system and retina, today announced that members of its management team willRHEA-AIneutral